References
- Cleemput I, Neyt M, Thiry N, et al. Threshold values for cost-effectiveness in health care Health Technology Assessment (HTA). Brussels (BE): Belgian Health Care Knowledge Centre (KCE); 2008. [ cited 2020 Oct 11]; [ 86 screens]. Available from: https://kce.fgov.be/sites/default/files/atoms/files/d20081027396.pdf
- Guinness L, Wiseman V. Introduction to Health Economics. Maidenhead (UK): Open University Press; 2011.
- McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26(9):733–744.
- Nanavaty M, Kaura S, Mwamburi M, et al. The use of incremental cost-effectiveness ratio thresholds in health technology assessment decisions. J Clin Pathways 2016;2:29–36.
- Guide to the methods of health technology appraisal. National Institute for Health and Care Excellence (NICE) [Internet]. 2004 Apr [ cited 2020 Oct 11]; [54 screens]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/191504/NICE_guide_to_the_methods_of_technology_appraisal.pdf
- Guide to the methods of health technology appraisal. National Institute for Health and Care Excellence (NICE) [Internet]. 2013 Apr 4 [ cited 2020 Oct 11]; [93 screens]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
- Hutchings A, Harris M, Pericleous L, et al. Assessing innovation of end-of-life treatments appraised by NICE [Internet]. 2012 Oct 12 [cited 2020 Oct 11]; [11 screens]. Available from: https://www.slideshare.net/HtaiBilbao/assessing-innovation-of-endoflife-treatments-appraised-by-nice
- Stewart G, Eddowes L, Hamerslag L, et al. The impact of NICE’s end-of-life threshold on patient access to new cancer therapies in England and Wales. Value in Health. 2014;17(3):A6.
- Crump H. The cancer drugs fund: a question of value(s) [Internet]. 2015 Jan 13 [ cited 2020 Oct 11]; [about 3 screens]. Available from: https://www.nuffieldtrust.org.uk/news-item/the-cancer-drugs-fund-a-question-of-value-s
- Appraisal and funding of cancer drugs from July 2016 (including the new cancer drugs fund) – a new deal for patients, taxpayers and industry. NHS England Cancer Drugs Fund Team [Internet]. 2016 Jul 8 [ cited 2020 Oct 11]; [65 screens]. Available from: https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf
- Guide to the processes of technology appraisal. National Institute for Health and Care Excellence (NICE) [Internet]. 2014 Sep 2, updated 2018 [cited 2020 Oct 11]; [101 screens]. Available from: https://www.nice.org.uk/process/pmg19/resources/guide-to-the-processes-of-technology-appraisal-pdf-72286663351237
- Macaulay R, Udechuku A Inflation, inflexibility and irrelevance – the need for inflation to be accounted for in ICER thresholds [Internet]. 2015 Nov [cited 2020 Oct 11]; [12 screens]. Available from: https://pdfs.semanticscholar.org/e670/ea2111663522c7bc6c55d174299018b53c07.pdf
- Towse A. Should NICE’s threshold range for cost per QALY be raised? yes. BMJ 2009;338:b181.
- Health sector cost index update. Health Care Supply Association (HCSA) [Internet]. 2018 Feb 19 [cited 2020 Oct 11]; [1 screen]. Available from: https://nhsprocurement.org.uk/health-sector-cost-index-update/
- NICE technology appraisal guidance (NICE) [Internet]. 2019 [cited 2021 Mar 11]; [1 screen]. Available from: https://www.nice.org.uk/guidance/published?type=ta&fromdate=January%202019&todate=December%202019
- Raftery J. Should NICE’s threshold range for cost per QALY be raised? No. BMJ 2009;338:b185.
- House of Commons Health Committee. National institute for health and clinical excellence: first report of session 2007–08. Vol. 1. London (UK): The Stationary Office; 2008.
- Claxton K, Martin S, Soares M, et al., Methods for the estimation of the NICE cost effectiveness threshold. Health Technol Assess. 2015;19(14).
- Dakin H, Devlin N, Feng Y, et al. The influence of cost-effectiveness and other factors on NICE decisions. Health Econ. 2015;24(10):1256–1271.